GlobeNewswire: Scythian Biosciences Corp. Contains the last 10 of 55 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T10:01:20ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/10/25/1627136/0/en/Scythian-Biosciences-Announces-Name-Change-to-SOL-Global-Investments-Corp.html?f=22&fvtc=4&fvtv=37310Scythian Biosciences Announces Name Change to SOL Global Investments Corp.2018-10-25T12:30:00Z<![CDATA[TORONTO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company”) (CSE:SCYB) (Frankfurt:9SB) (OTC – Nasdaq Intl:SCCYF) is pleased to announce that the Company has changed its name from “Scythian Biosciences Corp.” to “SOL Global Investments Corp.”]]>https://www.globenewswire.com/news-release/2018/10/23/1625275/0/en/Scythian-Biosciences-Makes-Strategic-Investment-in-Verano-Holdings-with-188-Million-USD-Transaction.html?f=22&fvtc=4&fvtv=37310Scythian Biosciences Makes Strategic Investment in Verano™ Holdings with $188 Million USD Transaction2018-10-23T11:00:00Z<![CDATA[Scythian Invests USD$88 Million in Verano Class B Membership Units]]>https://www.globenewswire.com/news-release/2018/10/12/1620519/0/en/Scythian-Biosciences-Applauds-the-UK-Government-s-Decision-to-Legalize-Medical-Cannabis.html?f=22&fvtc=4&fvtv=37310 Scythian Biosciences Applauds the UK Government’s Decision to Legalize Medical Cannabis2018-10-12T12:15:00Z<![CDATA[Scythian’s Chief Medical Officer, The Famed Dr. Barnes, Receives National Praise for His Advocacy, Education and Tireless Leadership from Government, Media and Medical Organizations to Assist in Making This Major Event Happen]]>https://www.globenewswire.com/news-release/2018/10/11/1619914/0/en/Scythian-Biosciences-Announces-Major-Milestone-in-U-S-Expansion.html?f=22&fvtc=4&fvtv=37310Scythian Biosciences Announces Major Milestone in U.S. Expansion2018-10-11T12:15:00Z<![CDATA[Florida Department of Health Approves CannCure’s Purchase of 60% of the Equity of 3 Boys Farms Including the License to Operate as a Medical Marijuana Treatment Center in Florida]]>https://www.globenewswire.com/news-release/2018/10/03/1600748/0/en/Scythian-Biosciences-Appoints-Brady-Cobb-as-CEO.html?f=22&fvtc=4&fvtv=37310Scythian Biosciences Appoints Brady Cobb as CEO2018-10-03T12:41:38Z<![CDATA[Company Also Names Andy DeFrancesco Chief Investment Officer Company Also Names Andy DeFrancesco Chief Investment Officer]]>https://www.globenewswire.com/news-release/2018/10/01/1587709/0/en/Scythian-Biosciences-Announces-Intention-to-Commence-Normal-Course-Issuer-Bid-to-Repurchase-up-to-5-of-its-Common-Shares.html?f=22&fvtc=4&fvtv=37310Scythian Biosciences Announces Intention to Commence Normal Course Issuer Bid to Repurchase up to 5% of its Common Shares2018-10-01T12:00:00Z<![CDATA[TORONTO, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (“Scythian” or the “Company”) (CSE:SCYB) (Frankfurt: 9SB) (OTC – Nasdaq Intl: SCCYF) announced its intention to commence a normal course issuer bid (“NCIB”), under which the Company may purchase up to 2,451,861 of the Company’s common shares, representing approximately 5% of its issued and outstanding common shares (the “Shares”). The Company is commencing the NCIB because it believes that, from time to time, the market price of its Shares may not fully reflect the underlying value of the Company’s business and future prospects. Scythian believes that, at such times, the repurchase of its Shares for cancellation represents an appropriate use of the Company’s financial resources and will enhance shareholder value.]]>https://www.globenewswire.com/news-release/2018/09/28/1586492/0/en/Scythian-Biosciences-Appoints-Peter-Liabotis-as-CFO.html?f=22&fvtc=4&fvtv=37310Scythian Biosciences Appoints Peter Liabotis as CFO2018-09-28T12:32:12Z<![CDATA[TORONTO, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Peter Liabotis, a veteran senior corporate finance executive and certified public accountant, has been appointed Chief Financial Officer of Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (Frankfurt:9SB) (OTC – Nasdaq Intl: SCCYF), a company that invests in leading cultivation, distribution and retail operators in the U.S. cannabis industry.]]>https://www.globenewswire.com/news-release/2018/09/27/1577418/0/en/Scythian-Biosciences-Closes-Strategic-Sale-of-Latin-American-and-Caribbean-Assets.html?f=22&fvtc=4&fvtv=37310Scythian Biosciences Closes Strategic Sale of Latin American and Caribbean Assets2018-09-27T16:02:43Z<![CDATA[Scythian Received 15,678,310 common shares of Aphria Inc. as Consideration for the Sale]]>https://www.globenewswire.com/news-release/2018/09/21/1574276/0/en/Scythian-Biosciences-Closes-Acquisition-of-MMJ-International-Investments-Inc.html?f=22&fvtc=4&fvtv=37310Scythian Biosciences Closes Acquisition of MMJ International Investments Inc.2018-09-21T12:00:00Z<![CDATA[Closing of Argentine Acquisition is Key Benchmark in Finalization of Previously Announced $193 Million Sale of Assets in Latin America, Which as of Prior Day Close was Valued At Approximately $313 Million]]>https://www.globenewswire.com/news-release/2018/09/17/1571668/0/en/Scythian-Biosciences-Announces-Successful-Results-of-Special-Meeting-of-Shareholders.html?f=22&fvtc=4&fvtv=37310Scythian Biosciences Announces Successful Results of Special Meeting of Shareholders2018-09-17T12:00:00Z<![CDATA[Shareholders Approve Strategic Sale of Latin American Assets to Aphria in Exchange for 15,678,310 shares of Aphria (TSX:APH)]]>